In a nutshell This study aimed to investigate the long-term effectiveness of the combination of ibrutinib, bendamustine, and rituximab in relapsed/unresponsive chronic lymphocytic leukemia/small lymphocytic lymphoma. This study concluded that this combination was safe and effective in the long-term in these patients. Some background...
Read More
In a nutshell This trial is aiming to examine the effectiveness of an experimental drug, AMXI-5001, in patients with advanced breast cancer. The main outcomes that are to be measured in this trial are side effects and the response to treatment. This trial is going to be carried out in California, Tennessee, and Florida, the United States. The...
Read More
In a nutshell This trial was carried out to examine the long-term safety and effectiveness of daratumumab (Darzalex) plus bortezomib (Velcade) and dexamethasone (Dexasone) in patients with previously treated multiple myeloma (MM). The authors concluded that after 3-years this treatment maintained benefit and...
Read More
In a nutshell This article was carried out to analyze trials carried out in order to assess the role of maintenance therapy in transplant-ineligible (TI) patients with multiple myeloma (MM) following induction therapy. The authors found that maintenance therapy increases survival without disease worsening in these patients. Some background MM is...
Read More
In a nutshell This study assessed the use of daratumumab (Darzalex) plus bortezomib (Velcade)/dexamethasone (Dexasone) or D-Vd versus bortezomib/dexamethasone (Vd) alone as a treatment for patients with high-risk multiple myeloma (MM). The authors found that D-Vd was effective and showed good tolerability...
Read More
In a nutshell This trial is aiming to examine the effectiveness and safety of atezolizumab (Tecentriq) and tiragolumab compared to durvalumab (Imfinzi) in stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed and has previously been treated with concurrent (at the same time) platinum-based chemoradiation therapy (CRT)....
Read More
In a nutshell This trial is aiming to investigate the effectiveness of stereotactic body radiotherapy (SBRT) boost for the treatment in patients with high-risk prostate cancer (PCa). The main outcome that will be measured will be the quality of life (QoL) of patients. This study is being carried out in Ontario, Canada. The details PCa is the...
Read More
In a nutshell The study evaluated outcomes of sorafenib (Nexavar) maintenance therapy after allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutation. The authors found that sorafenib maintenance therapy decreased the risks of relapse and mortality after HSCT in such...
Read More
In a nutshell This phase 2 trial is examining the effectiveness of TAS-102 (Lonsurf) plus oxaliplatin (Eloxatin) in the treatment of metastatic (spread to other parts of the body) colorectal cancer. The main outcome to be measured will be the overall response to the treatment rate. This study is being conducted in New Jersey, US. The details...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of allogeneic stem cell transplantation (alloSCT) after immune checkpoint inhibitor (ICI) treatment in patients with classic Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and has very good outcomes in these...
Read More
In a nutshell The study evaluated the outcomes of second autologous stem cell transplantation (ASCT2) in patients with relapsed/refractory Hodgkin lymphoma (r/r-HL) after a first transplantation (ASCT1). The main finding was that ASCT2 was safe and relatively effective in such patients. Some background ASCT replaces cancerous bone marrow with healthy...
Read More
In a nutshell This study looked at using both chemotherapy and blinatumomab (Blincyto) prior to stem cell transplant (SCT) for patients with relapsed or unresponsive aggressive non-Hodgkin lymphoma (NHL). It found that blinatumomab is an effective second salvage for patients who did not fully respond to chemotherapy. Some background NHL is a...
Read More
